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REVIEW
Systematic review of the cost eVectiveness of
prophylactic treatments in the prevention of
gastropathy in patients with rheumatoid arthritis
or osteoarthritis taking non-steroidal
anti-inflammatory drugs
Hiske E M van Dieten, Ingeborg B C Korthals-de Bos, Maurits W van Tulder,
Willem F Lems, Ben A C Dijkmans, Maarten Boers
Abstract
A systematic review on the cost eVective-
ness of prophylactic treatments of non-
steroidal anti-inflammatory drug (NSAID)
induced gastropathy in patients with oste-
oarthritis or rheumatoid arthritis was con-
ducted. Two reviewers conducted the
literature search and the review. Both full
and partial economic evaluations pub-
lished in English, Dutch, or German were
included. The criteria list published in the
textbook of Drummond was used to deter-
mine the quality of the economic evalua-
tions. The methodological quality of three
randomised controlled trials (RCTs) in
which the economic evaluations obtained
probability estimates of NSAID induced
gastropathy and adverse events was as-
sessed by a list of internal validity criteria.
The conclusions were based on a rating
system consisting of four levels of evidence.
Ten economic evaluations were included;
three were based on RCTs. All evaluations
studied misoprostol as prophylactic treat-
ment: in one evaluation misoprostol was
studied as a fixed component in a combina-
tion with diclofenac (Arthrotec). All eco-
nomic evaluations comprised analytical
studies containing a decision tree. The
three trials were of high methodological
quality. Nine economic evaluations were
considered high quality and one economic
evaluation was considered of low methodo-
logical quality. There is strong evidence
(level “A”) that the use of misoprostol for
the prevention of NSAID induced gas-
tropathy is cost eVective, and limited
evidence (level “C”) that the use of Arthro-
tec is cost eVective. Although the levels of
evidence used in this review are arbitrary,
it is believed that a qualitative analysis is
useful: quantitative analyses in this field
are hampered by the heterogeneity of
economic evaluations. Existing criteria to
evaluate the methodological quality of eco-
nomic evaluations may need refinement
for use in systematic reviews.
Arthritis (rheumatoid arthritis and osteoarthri-
tis) is a common condition and the prevalence of
rheumatoid arthritis increases with age to 2% for
men and 5% for women over age 55, respec-
tively. The prevalence of osteoarthritis increases
from 4% at younger age to 85% over age 75.1
Patients with rheumatoid arthritis or osteo-
arthritis frequently use non-steroidal anti-
inflammatory drugs (NSAIDs) for treatment of
their arthritis.2 With the prevalence of arthritis,
the prevalence of NSAID use increases with
advancing age: about half of all NSAID
prescriptions are for patients aged 60 or older.3
Although NSAIDs are generally well toler-
ated, adverse gastrointestinal events occur in a
small but important percentage of patients.
NSAIDs may cause adverse events ranging in
severity from asymptomatic mucosal damage,
abdominal pain, heartburn, and dyspepsia to
serious complications, such as haemorrhages
and perforated ulcers, requiring admission to
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hospital. The prevalence of mild adverse events
ranges from 5% to 50% for patients treated
with NSAIDs. More severe adverse events are
less common and have an annual incidence of
1–2%. Because patients with arthritis who fre-
quently use NSAIDs often have other risk fac-
tors (advanced age, high doses of NSAIDs,
presence of comorbid conditions, previous
ulcer), this patient group is particularly at risk
of gastrointestinal complications.4 5 Previous
research has shown that 5.4% of patients with
NSAID induced adverse events are admitted to
hospital.6 The costs of treating these adverse
events are high and include costs of drugs,
admission to hospital, and doctor’s fees.
Therefore, it is important to have cost eVec-
tive prophylactic treatments that decrease the
incidence of adverse events. In the past decade
many economic evaluations on the cost eVec-
tiveness of such treatments have been con-
ducted. The conclusions of these evaluations
are not consistent, ranging from cost saving
and cost eVective to costly. Several reviews have
summarised the literature, but a systematic
approach, including assessment of the meth-
odological quality of the economic evaluations,
was not included in these reviews.7–10
This article presents a systematic review of
the cost eVectiveness of prophylactic treat-
ments in the prevention of gastropathy in
patients with rheumatoid arthritis or osteoar-
thritis taking NSAIDs.
This review aimed at evaluating the cost
eVectiveness of prophylactic treatments to pre-
vent gastropathy by reviewing and assessing the




Two reviewers (HvD and IK) together identi-
fied all relevant studies by searching several
electronic databases—namely, Medline (1966
to November 1999), Embase (1988 to Septem-
ber 1998), the NHS Economic Evaluation
Database from the University of York, and the
Cochrane Library, 1999, issue 1. Keywords
used were “non-steroidal anti-inflammatory
agents”, “rheumatoid arthritis”, “osteoarthri-
tis”, “costs”, “cost analysis”, “cost-benefit
analysis”, “digestive system diseases”, “gastri-
tis”, “misoprostol”, ”stomach ulcer”, “peptic
ulcer perforation”, “omeprazole” and “proton
pump inhibitor”. No further text words were
used to identify economic evaluations.
Furthermore, references given in relevant
identified publications and reviews were
screened. After reviewing the abstract or, in
cases where there was any doubt, a copy of the
full article, economic evaluations were in-
cluded in the review if (a) the study contained
a full or partial economic evaluation, (b) the
subjects of study were patients with osteoar-
thritis or rheumatoid arthritis taking NSAIDs,
and (c) the study assessed any type of prophy-
lactic treatment for NSAID induced gastropa-
thy. The decision on the inclusion of the stud-
ies found in the literature search was not
blinded, because the two reviewers were unfa-
miliar with the literature in the field of
rheumatic diseases. For practical reasons, only
economic evaluations published in English,
Dutch, or German were included.
METHODOLOGICAL QUALITY ASSESSMENT
Economic evaluations may be conducted
alongside randomised clinical trials (RCTs),
but may also consist of a decision analysis. The
methodological quality assessment in this
review was, therefore, divided into two parts.
Firstly, the quality of the economic evalua-
tions was assessed independently by two
reviewers (HvD and IK) with the “checklist for
assessing economic evaluations” published by
Drummond et al11 (table 1).
Items could be scored as positive, negative,
or unclear. Economic evaluations that scored
50% or more of the items positive were defined
as studies of high methodological quality,
whereas less than 50% was considered low
methodological quality.
Secondly, the same two reviewers independ-
ently assessed the methodological quality of the
original RCTs. Only items related to the inter-
nal validity of RCTs, using a criteria list which
has been recommended and used by the
Cochrane Back Review Group for trials in the
field of musculoskeletal disorders,12 were used
(table 2).
Items could be scored as positive, negative,
or unclear. RCTs that fulfilled 50% or more of
the internal validity items were considered of
high methodological quality. RCTs that ful-
filled fewer then 50% of the items positive were
considered low quality. Disagreements be-
tween the reviewers were solved by consensus.
ANALYSIS
The results of the economic evaluations were
not statistically pooled, for two reasons:
1 The economic evaluations were conducted
in diVerent countries with diVerent health-
care systems. These diVerences include
diVerences in practice variations, financial
incentives, etc which can lead to situations
where intervention X is cost eVective in
country A and costly in country B.10
2 The assumptions used in the economic
evaluations varied widely.
Instead, a qualitative analysis was conducted
with a modified version of a rating system used
in the Cochrane Back Review Group. The rat-
ing system consisted of four levels of scientific
evidence.12
1 Strong evidence provided by generally con-
sistent findings in multiple high quality eco-
nomic evaluations based on high quality
RCTs or a meta-analysis.
2 Moderate evidence provided by generally con-
sistent findings in multiple high quality eco-
nomic evaluations based on low quality
RCTs or observational studies
3 Limited evidence provided by generally con-
sistent findings in low quality economic
evaluations.
4 Conflicting evidence: inconsistent findings.
SENSITIVITY ANALYSIS
In a sensitivity analysis the influence of the
threshold for high methodological quality of
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economic evaluations and RCTs was evaluated
by varying the cut oV point (that is, using 60%
or 70% as a threshold for high methodological
quality). The influence on the methodological
quality of the items that were scored as
“unclear” was evaluated by assuming that an




We identified 396 citations in Medline and 248
in Embase. After screening the abstracts and,
if necessary, full articles, we reached agree-
ment on the inclusion of 10 economic
evaluations.13–23 All economic evaluations were
found in Medline, six were also found in
Embase, and three economic evaluations were
also found with the use of the NHS database.
Nine studies were published in English and
one in German.
All evaluations studied misoprostol as pro-
phylactic treatment. In one evaluation miso-
prostol was studied as a fixed component in
combination with diclofenac (Arthrotec).
ECONOMIC EVALUATIONS
All economic evaluations included in this
review were analytical decision studies con-
taining a decision tree. The probability
estimates of NSAID induced gastropathy
and adverse events of prophylactic treatment
in the economic evaluations were derived from
either a previously conducted RCT, a
meta-analysis, an observational study, or
selected literature (combination of RCTs
and/or observational studies) and assigned to
the change nodes in the decision trees. The
decision trees used in the economic evalua-
tions were basically similar. They all started
with a decision node for the diVerent prophy-
lactic treatments. The decision trees contained
branches with change nodes reflecting the
Table 1 Criteria list for the quality assessment of economic evaluations11: each scored as positive, negative or unclear
Items Ref 13 Ref 14 Refs 15, 16 Ref 17 Ref 18 Ref 19 Ref 20 Ref 21 Ref 22 Ref 23
1. Was a well defined question posed in answerable form? ? + − + − + + + + +
1.1 Did the study examine both costs and eVects? + + + + − + + + + +
1.2 Did the study include comparison of alternatives? + + + + + + + + + +
1.3 Was a viewpoint for the analysis stated? + − − + − + − − + −
2. Was a comprehensive description of the alternatives given? + + + + + + + + + +
2.1 Were any important alternatives omitted? + + + + + + + + + +
2.2 Was a do-nothing alternative considered? + + + + + + + + + +
3. Was the eVectiveness of the programmes established? + + ? + + + + ? + +
3.1 Was this done through a randomised, controlled clinical trial? + − − + ? + + + + +
3.2 Was eVectiveness established through an overview of clinical
studies?
− + − − + − − − − −
3.3 Were observational data or assumptions used to establish
eVectiveness?
+ + + + + + + + + +
4. Were all the important and relevant costs and consequences
identified?
+ + − + ? + + + + +
4.1 Was the range wide enough for the research question at hand? + + + + + + + + + +
4.2 Did it cover all relevant viewpoints? ? − − − ? − + − ? −
4.3 Were capital costs, as well as operating costs, included? − − ? + − − + + + ?
5. Were costs and consequences measured accurately in appropriate
physical units?
+ + + + + + + + + +
5.1 Were any of the identified items omitted from measurement? + − + + − ? − + + +
5.2 Were there any special circumstances that made measurement
diYcult?
+ − + + − − − − − −
6. Were costs and consequences valued credibly? + + ? + + + + + + ?
6.1 Were the sources of all values clearly identified? + − + + + + + + + −
6.2 Were market values employed for changes in resources gained
or depleted?
− − − − − − + + ? −
6.3 Were adjustments made to approximate market values? ? − ? − − − ? + − +
6.4 Was the valuation of consequences appropriate for the question
posed?
− + + + − − + + + +
7. Were costs and consequences adjusted for diVerential timing? − ? − − − − − − − −
7.1 Were costs and consequences discounted? − − − − − − − − − −
7.2 Was any justification given for the discount rate used? − − − − − − − − − −
8. Was an incremental analysis performed? − + + + + − − − + −
8.1 Were the additional costs compared with the additional eVects? − + + + + − − − + −
9. Was allowance made for uncertainty in the estimates? + + + + + + + + + +
9.1 Were appropriate statistical analyses performed? + + + + + + + + + +
9.2 Was justification provided for the ranges of values? + + + + + + + − − +
9.3 Were study results sensitive to changes in the values? ? + + + − + + + − +
10. Did the study results include all issues of concern to users? + + ? + − − ? − + −
10.1 Were the conclusions of the analysis based on some overall
index or ratio?
+ + + + − − + − + −
10.2 Were the results compared with those of others? − + + + − − + − + +
10.3 Did the study discuss the generalisability of the results? + + + + + + + + + −
10.4 Did the study take account of other important factors? + + − − − ? − − − −
10.5 Did the study discuss issues of implementation? − − − + − − − − − −
% Positive 61 66 55 79 45 53 66 58 68 53
Table 2 Criteria list for assessing the methodological quality of (randomised) clinical








1. Concealment of treatment allocation
1a. Adequate allocation concealment − − +
1b. Generation of the allocation sequence − − +
2. Similarity of baseline characteristics + + +
3. Blinding of outcome assessor + ? +
4. Blinding of patients − + +
5. Blinding of care provider − ? +
6. Identical timing of outcome assessment + + ?
7. Withdrawals and dropouts
7a. During intervention period + + −
7b. During follow up period + + −
8. Adherence to interventions (compliance) − − ?
9. Co-interventions ? − +
10. Intention to treat analysis + + ?
% Positive 50 50 58
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probabilities of adverse events during prophy-
lactic treatment. Figure 1 shows the structure
of all branches.
METHODOLOGICAL QUALITY OF ECONOMIC
EVALUATIONS
Applying a cut oV point of >50% positive
items resulted in nine high quality
evaluations.13–17 19–23 Only one evaluation was of
low methodological quality18 (table 1).
The viewpoint of the evaluation (item 1.3)
was stated in only four evaluations.13 17 19 22 The
viewpoints used in these four evaluations were a
societal viewpoint,13 19 a viewpoint of hospital
based services of the provincial healthcare
plan,17 and the provincial healthcare plan.22 The
viewpoint of the evaluation has influence on the
costs included in an economic evaluation and
the type of outcomes measured.12 Seven eco-
nomic evaluations13 17 19–23derived data on the
eVectiveness of prophylactic treatments from
RCTs.24–26 Subitems 3.3 on the use of observa-
tional data and 4.1 on the range of costs and
consequences were always scored positive.
Capital costs and operating costs (item 4.3)
were incorporated in four studies,17 20–22 while
five studies omitted these costs and in two
studies it was unclear whether these costs
were incorporated or not.15 16 23 Three
evaluations13 15–17 accounted for special circum-
stances (item 5.2), such as shared operating
rooms or overhead costs, the others did not.
Only two economic evaluations20 21 used cost
prices instead of market prices (item 6.2), and
for one evaluation22 it was unclear whether cost
prices or market prices were used. Neither one
of the evaluations adjusted cost and conse-
quences for diVerential timing. An incremental
analysis of costs and consequences (item 8) was
conducted in five evaluations.14–18 22 Six eco-
nomic evaluations13–17 20 22 presented their re-
sults as cost eVectiveness ratios (item 10.1). In
six evaluations14–17 20 22 23 the results of the evalu-
ation were compared with those of other evalu-
ations (item 10.2). Only one of the evaluations17
discussed implementation (subitem 10.5). This
may be due to the fact that the treatment of
patients with rheumatoid arthritis or osteoar-
thritis with some kind of gastroprotection is
already implemented in many healthcare sys-
tems. Therefore, the implementation of the
results of the economic evaluations will not
require great eVort or will not lead to major
changes within healthcare systems.
The 10 economic evaluations were diVerent
in several aspects. Table 3 shows the most
striking diVerences.
Three economic evaluations13 20 21 stated that
the use of misoprostol as a prophylactic
treatment was cost eVective. The economic
evaluation of Carrin and Torfs13 resulted in cost
savings ranging from $78 for widows, orphans,
pensioners, and invalids and $84 for employees
in university hospitals and from $74 to $79 in
general hospitals respectively. Lives saved were
slightly above 14 per 10 000 in university hos-
pitals and 14.7 in general hospitals. The
analytical decision study by Jönsson and
Haglund20 yielded $175 for each patient treated
with misoprostol compared with $208 for each
patient with no prophylaxis. Knill-Jones et al21
showed that $11 was saved for each case
treated with misoprostol over three months in
Scotland and $16 in England.
Goldstein concluded that the use of a
combination of diclofenac and misoprostol
(Arthrotec) was cost eVective compared with
the use of regular NSAIDs in the prevention of
NSAID induced gastropathy.18 A cost/patient
ratio of $1153 for all NSAID regimens and
$939 for Arthrotec regimens was presented.
Four economic evaluations14 17 19 22 stated
that the use of misoprostol as a prophylactic
treatment was cost eVective under certain con-
ditions. These conditions included, for exam-
ple, the ulcer rate, admission to hospital rate,
compliance, patient group, and drug prices.
Prophylactic treatments were more cost eVec-
tive if the ulcer rate and admission to hospital
rate were high and the price of the prophylactic
pharmaceutical was low.
The economic evaluation conducted by
Schwarz23 reported only on costs.
One economic evaluation15 16 conducted a
cost-utility analysis and concluded that the use
of misoprostol costs more and provides no
additional quality of life than no prophylaxis.
The overall conclusion, however, was that
these economic evaluations clearly showed that
the use of prophylactic treatments (misopros-
tol) for the prevention of gastropathy is cost
eVective.
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METHODOLOGICAL QUALITY OF (RANDOMISED)
CLINICAL TRIALS
From three RCTs probability estimates of
NSAID induced gastropathy and adverse
events were derived.24–26 The other economic
evaluations derived their probability estimates
from a meta-analysis,27 a cohort study,28 or
selected literature. Table 2 shows the results of
the consensus on the methodological quality
assessment of these RCTs. Previous research
has shown that items dealing with randomisa-
tion, blinding, and dropouts, in particular,
might be associated with bias.29
All three RCTs were considered to be high
quality, according to our definition. The trial
conducted by Silverstein et al26 was a double
blinded, randomised clinical trial in which
8843 patients participated (mean age 67,
6–70% women, 83% white) and with only a
few dropouts. The other two trials24 25 were sin-
gle blinded, had more than 20% dropouts, and
included data on 421 patients (mean age 58.9,
65% women, 83% white) and 356 patients
(mean age 60.1, 56% women, 89% white)
respectively.
In the RCT conducted by Silverstein,26 in
contrast with the RCTs conducted by
Agrawal24 and Graham,25 the rates of major
healthcare resource use were low, and probably
reflect more closely the real world than the high
rates estimated in the other two trials.
There was no evidence of a relation between
the quality of the RCTs and the quality of eco-
nomic evaluations because all RCTs were of
high methodological quality. Nevertheless, all
high quality economic evaluations derived their
probability estimates from RCTs or meta-
analyses and not from selected literature or
cohort studies.
COST EFFECTIVENESS
Nine economic evaluations, eight full and one
partial,23 compared prophylactic treatment
with misoprostol with placebo. One full
economic evaluation18 compared Arthrotec
with NSAID + misoprostol, NSAID + H2
receptor antagonists, and NSAIDs alone.
Three high quality economic evaluations13 20 21
(level of evidence “A”) concluded that the use of
misoprostol as a prophylactic treatment for the
prevention of gastropathy was cost eVective.
Three high quality economic evaluations17 19 22
(level of evidence “A”) and one evaluation14 of
moderate quality (level of evidence “B”) stated
that the use of misoprostol was cost eVective,
though under certain conditions. One partial
high quality23 economic evaluation reported only
on the costs of treatment with a pharmaceutical
prophylaxis. Gabriel stated that prophylactic
treatment with misoprostol is costly, unless it is
used in high risk NSAID users.15 16 The distinc-
tion in this article between prophylaxis for
elderly NSAID users and prophylaxis for all
NSAID users explains the diVerent result of this
economic evaluation compared with the others.
Goldstein concluded that the use of Arthro-
tec generates fewer costs than NSAID + miso-
prostol, NSAID + H2 receptor antagonists, and
NSAIDs alone (level of evidence “C”).18
The economic evaluation conducted by
Maetzel et al22 was the only evaluation that
derived the probability estimates of NSAID
induced gastropathy and adverse events of pro-
phylactic treatments from the RCT of
Silverstein.26 This RCT reflects more the real
life eVectiveness of prophylactic treatment than
the RCTs conducted by Agrawal24 and
Graham.25 Therefore, the economic evaluation
of Maetzel is the best approach to the cost
Table 3 Study characteristics
Study characteristics: Ref 13 Ref 14 Refs 15, 16 Ref 17 Ref 18 Ref 19 Ref 20 Ref 21 Ref 22 Ref 23
Patients
Osteoarthritis x x x x x
Rheumatoid arthritis x x x x x
Treatment
Misoprostol x x x x x x x x x x
Placebo x x x x x x x x x x
H2 receptor antagonist x
Misoprostol/diclofenac x
Study design
Meta-analysis x x x
RCT x x x x x x x
Cohort study x
Population survey x
Selected literature x x
Costs
* Direct costs:
Admission to hospital x x x x x x x x x x
Ambulatory care x x x x x x x x x
Drug treatment (prophylaxis) x x x x x x x x x x
Treatment of adverse events x x
Doctor’s visit x x x x
* Indirect costs x
Primary outcome
Cost/lives saved x x
Cost/adverse events averted x x
Cost/QALY† x
Cost/patient x x x x
Cost only x
Misoprostol compared with placebo:
Cost eVective x a* x x




†QALY = quality adjusted life year.
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eVectiveness of the use of prophylactic treat-
ments in daily practice.
The overall conclusion is that there is strong
evidence (level “A”) that the use of misoprostol
is cost eVective as prophylactic treatment in the
prevention of gastropathy in patients with
arthritis.
SENSITIVITY ANALYSIS
Varying the cut oV point between >60% and
>70% positive items resulted in five13 14 17 20 21
and one17 high quality economic evaluation
respectively (table 1).
A cut oV point of >60% positive items
resulted in four evaluations on the cost eVective-
ness of misoprostol13 17 20 22 with level of evidence
“A”. A cut oV point of >70% positive items
yielded one evaluation17 with level of evidence
“A”. Varying the cut oV point, however, did not
change the overall conclusion of this review.
Changing the “unclear” items to “positive”
items in the methodological quality assessment
also resulted in the same conclusions.
Discussion
There was strong evidence (level “A”) that
misoprostol is cost eVective in the prevention of
NSAID induced gastropathy. This overall con-
clusion may be biased for two reasons. Firstly,
it is possible that economic evaluations with a
negative outcome are not published and, there-
fore, not included in this review. Secondly, it
might be that the probability estimates of
NSAID induced gastropathy and adverse
events used in the economic evaluations are
based on patients with a high risk of developing
gastrointestinal complications, which makes an
intervention more cost eVective for those
patients than for patients with moderate risk.
The slightly diVerent conclusions reached by
the economic evaluations may be explained by
the diVerent assumptions that were used.
Goldstein,18 like Plosker and Lamb,29 con-
cluded that the use of Arthrotec as prophylaxis
for gastropathy was cost eVective compared
with the use of NSAID + misoprostol, NSAID
+ H2 receptor antagonists, or NSAIDs alone.
However, this evaluation was of poor methodo-
logical quality.
Our systematic review is methodologically
diVerent from earlier conducted reviews7–10 on
this subject for several reasons.
Firstly, this is the first systematic review on
this subject that contains a systematically
performed literature search conducted by two
researchers, according to the most up to date
methodology.30 31 The previously conducted
reviews on this subject only searched Medline,7 8
or the database in which the economic evalua-
tions were found was not mentioned.9 10 The
number of economic evaluations included in
these reviews ranged from five to eight, whereas
we identified 10 economic evaluations. After
correction for the date of publication, nine of the
10 economic evaluations included in this review
were published at the time of publication of the
above mentioned reviews.
Secondly, the methodological quality of the
RCTs from which the probability estimates of
NSAID induced gastropathy and adverse
events were derived was assessed. This is
necessary because the quality of an economic
evaluation of medical technologies may depend
upon the quality of the assessment of the clini-
cal eVectiveness of these technologies.32 High
quality RCTs are more likely to provide valid
estimates and, consequently, economic evalua-
tions using data from these RCTs are also less
likely to provide biased results.
Thirdly, we used the criteria list of Drum-
mond et al11 to assess the methodological qual-
ity of economic evaluations. Not every item or
subitem in this criteria list was suitable for
quality assessment of the economic evaluations
included in this review. Subitem 1.2 and item 2
and its subitems both referred to the alterna-
tives included in the evaluation (table 1).
Subitems 1.3 and 4.2 were both questions
about the viewpoint of the evaluation. The
scoring of item 7 and its subitems on discount-
ing of costs and consequences depends on the
time horizon of the study. It is unclear which
items in the criteria list of Drummond are
related to the internal validity of an economic
evaluation, which indicates the possibility of
bias in the results of a study. Therefore, to
assess the quality of economic evaluations, a
criteria list like the list with items related to the
internal validity of RCTs31 has to be developed.
The conclusions of this review are slightly
diVerent from those of earlier conducted
reviews. Stucki stated that “the absence of firm
data on the rate of NSAID induced gastric
ulcers reduced by misoprostol makes it impos-
sible to conclude whether it is cost eVective in
patients with chronic arthritis who use
NSAIDs”.7 In the review published by Gabriel9
the authors came to the conclusion that “the
widespread use of misoprostol prophylaxis not
only has important economic consequences,
but has important consequences for quality of
life. More research is needed to address the
clinical trade-oVs between cost and quality of
life that are inherent in the use of NSAIDs”.
All evaluations included in this review were
decision analytical studies. As described above,
some items and subitems of the criteria list of
Drummond were less appropriate for the qual-
ity assessment of these evaluations. If items 1.2,
3.3, 4.2, and 7 had not been incorporated in
the quality assessment of the economic evalua-
tions, the proportion of positively scored items
of all evaluations would have been higher.
All these studies contain decision trees
implying modulation and simulation of prob-
abilities on a fictive population. There are sev-
eral simulation models, such as the Markov
and Monte Carlo models. However, only two
economic evaluations mentioned the simula-
tion model used.15 16 18
There is evidence that some patients experi-
ence substantial losses in quality of life because
of adverse events of prophylactic drugs.9 How-
ever, only one economic evaluation included
quality of life and conducted a cost-utility
analysis.15 16 Future economic evaluations
should include such an analysis because it ena-
bles comparison of the cost-utility between dif-
ferent medical technologies.
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The time horizons of the economic evalua-
tions were relatively short, considering that
NSAID induced gastropathy may occur at any
time in the long term treatment of arthritis.
The cause of those short time horizons is that
the follow up periods used in the RCTs were
used as the time horizons in the economic
evaluations.
The levels of evidence used in this review
were arbitrary. We used a modified version of a
Cochrane rating system that is similar to the
rating system used by the Cochrane Back
Review Group. Other levels of evidence or rat-
ing systems are available. The choice is
arbitrary. The methodology of qualitative
analysis of systematic reviews of economic
evaluations should be further developed. How-
ever, we do believe that a qualitative analysis
using levels of evidence is a good alternative in
systematic reviews when a quantitative analysis
(meta-analysis) is either not possible or not
useful in cases where the study groups,
interventions, and outcomes of studies are too
heterogeneous.
To summarise, the results of this review con-
firmed that there is strong evidence that it is
cost eVective to prescribe misoprostol as
prophylactic treatment in arthritic patients tak-
ing NSAIDs in daily clinical practice.
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